SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is experiencing significant trading volume and upward momentum as investors speculate on its potential role in space infrastructure and satellite expansion projects tied to the anticipated SpaceX IPO. The community is actively discussing institutional accumulation and the stock's positioning as an infrastructure play, with many users focused on technical breakouts and potential long-term growth as the broader space sector gains traction.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following an exclusive U.S. deal for the Japanese Tokyo-172 BCG strain, a move investors see as a crucial step toward securing a reliable supply chain and unblocking first-line market penetration for Anktiva. The community is actively discussing this news alongside ongoing FDA workshops and anticipation for potential label expansions, fueling significant speculation about a near-term short squeeze.

Robo.ai, Inc. engages in the design and development of smart electric vehicles. It aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology. The company was founded in 2016 and is headquartered in Dubai, United Arab Emirates.

Robo.ai Inc. - Ordinary Shares - Class B

Robo.ai Inc.

Robo.ai Inc. is experiencing extreme volatility driven by high short interest and retail enthusiasm surrounding its AI-driven video compression technology. The community is actively debating the sustainability of the price moves, with many traders focused on short-term momentum, potential squeeze setups, and the impact of frequent trading halts.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending as investors weigh its upcoming earnings report against significant volatility, while the community intensely debates its valuation and potential index inclusion impacts. Market participants remain sharply divided between those betting on continued AI-driven infrastructure growth and others warning of a potential bubble given the stock's rapid appreciation.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is seeing heightened interest following its Q1 results, which showed that revenue from AI-driven cloud infrastructure is surging, helping to offset declines in its legacy advertising business. Community sentiment remains polarized, with some investors focusing on the long-term potential of the company's AI agent ecosystem and autonomous driving segment, while others remain skeptical about the stock's performance and the broader economic headwinds facing Chinese equities.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is surging following the announcement of its acquisition of DustPhotonics, a strategic move that solidifies the companys expansion into the high-growth silicon photonics market. Investors are actively discussing the acquisition's potential to accelerate optical revenue and its role in strengthening Credo's position as a critical infrastructure provider in the AI data center connectivity landscape.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the Florida Power and Light Company (FPL) and NextEra Energy Resources and NEET (NEER). The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NextEra Energy is currently in the spotlight as investors debate the impact of its strategic pivot toward large-scale infrastructure projects designed to meet the surging electricity demand from AI-driven data centers. Community discussion is focused on the tension between the stock's long-term potential as a clean energy leader and its premium valuation, with participants actively weighing how the companys capital-intensive expansion plans will balance against regulatory headwinds and evolving energy policy.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing significant downward pressure and intense community scrutiny as the stock hovers near multi-year lows, fueling a heated debate among investors regarding its potential as a deep-value turnaround play versus fears of terminal decline. While some market participants are accumulating shares in anticipation of a potential sector rotation or recovery driven by major upcoming events, others are aggressively shorting the stock, citing weak fundamentals, sluggish sales, and a perceived loss of brand resonance.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is capturing investor interest as it pivots toward high-density edge data centers and modular power solutions, positioning itself to address the growing compute and energy bottlenecks facing hyperscalers. The community is actively discussing the company's strategic partnership with Fortress Investment Group and its potential to scale rapidly, with many focused on the interplay between its infrastructure capabilities and the escalating demand for localized AI processing power.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is seeing significant market activity driven by strong Q1 results that beat earnings expectations, paired with a major 10 million share stake disclosure from Situational Awareness. Community discussions are heavily centered on the stock's potential for a short squeeze due to elevated short interest, while investors weigh the impact of new institutional backing against volatility and the company's long-term infrastructure role in the AI data center space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Clene said earlier on Thursday that it plans to submit a New Drug Application for its lead ALS candidate CNM-Au8 in the third quarter of 2026 under the FDA’s accelerated approval pathway.</li><li>Roth Capital analyst dismissed the chances of the drug getting approval on a surrogate endpoint.&nbsp;</li><li>The analyst, however, reiterated a ‘Buy’ rating on the stock and a $30 price target.</li></ul> Shares of Clene Inc. (CLNN) fell 3% after hours on Thursday after a Roth Capital analyst dismissed the chances of the U.S. Food and Drug Administration approving its application for the investigational therapy CNM-Au8 in the treatment of amyotrophic lateral sclerosis on an accelerated basis as a “long shot.”Shares of the company rose 8% during regular trading hours but fell after hours following the analyst note.<h2 class="st-heading-2">Clene’s Plans For Its Investigational Therapy</h2>Clene said earlier on Thursday that it plans to submit a New Drug Application for its lead ALS candidate CNM-Au8 in the third quarter of 2026 under the FDA’s accelerated approval pathway. The FDA's Accelerated Approval pathway allows earlier approval of drugs treating serious or life-threatening conditions with unmet medical needs based on surrogate endpoints reasonably likely to predict clinical benefit, with mandatory confirmatory trials required post-approval to verify benefit.The company’s submission will rely on data showing statistically significant reductions in neurofilament light chain — a key biomarker of neuronal damage — following a constructive meeting with the FDA in the first quarter. Regulators signaled that the NfL results, along with correlations to improved survival and clinical outcomes, may support accelerated approval for ALS, the company said.“We were encouraged by the constructive dialogue during our recent Type C meeting with the FDA,” said Clene CEO Rob Etherington. “People living with ALS continue to need additional treatment options, and we believe CNM-Au8 has the potential to restore and protect neuronal health and function, leading to improved survival.” The company also said on Thursday that it intends to launch a confirmatory late-stage trial in Q1 2027, with overall survival as the primary endpoint.<h2 class="st-heading-2">Analyst Weighs In On Plans</h2>Roth Capital analyst Jonathan Aschoff said that the FDA's agreement to receive Clene's accelerated approval NDA for CNM-Au8 in treating ALS is a positive development, but the firm does not believe that the magnitude of change in neurofilament light will drive approval.The firm added that despite the dire ALS medical need, the much smaller NfL reduction with CNM-Au8 versus Biogen’s Qalsody stokes its pessimism. Qalsody is a prescription, FDA-approved medication specifically for adults with ALS, a progressive, fatal neurodegenerative disorder.Roth, however, reiterated a ‘Buy’ rating on the stock and a $30 price target.<h2 class="st-heading-2">How Did CLNN Retail Traders React?</h2>On Stocktwits, retail sentiment around CLNN stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<a href="https://stocktwits.com/symbol/CLNN">CLNN stock</a> has gained over 165% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rgnx-stock-on-track-for-worst-day-ever-as-big-q1-loss-cash-concerns-eclipse-duchenne-trial-success/cZX1zjuReSX">RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’  

Shares of the company rose 8% during regular trading hours but fell after hours following the analyst note. 

Equity

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of +38.00% and -62.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +15.39% and +0.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Clene (NASDAQ:CLNN) Major Shareholder Sells $34,827.95 in Stock

Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 5,795 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $6.01, for a total value of $34,827.95. Following the sale, the insider directly owned 271,774 shares in the...

Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 72,884 Shares

Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 72,884 shares of Clene stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average...

Promising Nanotechnology Stocks To Watch Today - May 5th

Onto Innovation, Clene, NVE, and Nano Dimension are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies whose...

Nanotechnology Stocks To Watch Today - May 4th

Onto Innovation, Clene, NVE, and Nano Dimension are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies whose core activities involve developing, manufacturing, or commercializing products and processes that man...

Clene's (CLNN) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reissued a "buy" rating and issued a $31.00 price target on shares of Clene in a research note on Monday...

<ul class="summary-bullets"><li>The agency said NfL could be used as a marker to predict patient benefit, but more data is still needed to confirm that link.</li><li>Clene plans to submit its NDA in the third quarter of 2026.</li><li>The firm’s CNM-Au8 has demonstrated a favorable safety profile with no serious treatment-related side effects.</li></ul>Shares of Clene Inc. (CLNN) climbed more than 8% on Monday after a positive update from the U.S. Food and Drug Administration signaled a potentially faster path to approval for its experimental ALS treatment.<a href="https://stocktwits.com/symbol/CLNN">CLNN shares</a> traded at their highest levels in 2026.<h2 class="st-heading-2">Clene To Submit NDA By Q3 2026</h2>According to the company, following a recent meeting, the FDA noted that its data, particularly changes in the neurofilament light (NfL) biomarker, may support a New Drug Application (NDA) under the accelerated pathway. The biomarker indicates active damage to nerve cells.The agency said NfL could be used as a marker to predict patient benefit, but more data is still needed to confirm that link. Clene plans to submit its NDA in the third quarter of 2026.“We are encouraged by the FDA’s careful evaluation of the benefits and risks associated with Clene’s ALS drug candidate, CNM-Au8, including the biomarker data the company provided. We are committed to working with the Agency on this filing and are conducting the Phase 3 confirmatory study for CNM-Au8, which we intend to commence in the first quarter of 2027,” said Rob Etherington, President and CEO of Clene.Clene’s experimental ALS drug CNM-Au8 showed strong biomarker and safety results. CNM-Au8 has also demonstrated a favorable safety profile with no serious treatment-related side effects reported.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for CLNN on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘extremely high’ message volumes.One user said the acceptance of the NDA is near certainty.<stembedurl>https://stocktwits.com/Takeover24/message/652164418</stembedurl>Another user said, despite the positive news, “retail investors have yet to grasp its true significance.”<stembedurl>https://stocktwits.com/Verudoxi/message/652161629</stembedurl>The stock has gained more than 5% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-cnsp-stock-surge-330-percent-today/cZQMtUXReJB">Why Did CNSP Stock Surge 330% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment

 The U.S. Food and Drug Administration noted that Clene’s data, particularly changes in the neurofilament light biomarker, may support a New Drug Application under an accelerated pathway.

Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug

FDA signals accelerated pathway for Clene's ALS drug CNM-Au8, with NDA filing planned and mixed technical indicators in focus.read more...

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

CLNN
Clene Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest CLNN News

CLNNClene Inc